Trial Search Results

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Primary:

To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.

Secondary Objectives:

To describe the safety and tolerability at this dose and schedule

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Novartis

Stanford Investigator(s):

Intervention(s):

  • Drug: zoledronic acid

Phase:

Phase 2

Eligibility


Inclusion Criteria:Patients: Who are 18 years of age and older Who have histologically
documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS greater
than 80%Life expectancy greater than 6 months Provide written consent pursuant to
regulatory requirements prior to initiation of study procedure Exclusion Criteria:Exclusion
Criteria: Patients: Any patient requiring continuous LHRH Any patient who has had an
orchiectomy Any patient with painful bone metastases Who have received chemotherapy for
prostate cancer Who have a abnormal serum creatine >2.5 Receiving any investigational drug
within the last 28 days Severe uncontrolled infection, diabetes, cardiac disease Patients
with fragility fractures, hyperparathyroidism, Pagets renal osteodystrophy will be excluded
History of non compliance to medical regimens or unwillingness to return for medical visits

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
6507361252